What Is the Future of Erectile Dysfunction Therapy?
Purpose of Review
Erectile dysfunction (ED) is a burden for the majority of men during their lifetime. Phosphodiesterase type-5 inhibitors are first-line treatment for men with ED; however, they are limited by on-demand dosing, short-term benefits, and reduced efficacy in difficult to treat populations such as men with diabetes mellitus or ED after radical prostatectomy.
Novel treatment options that offer a durable, tissue restorative approaches are being explored and potentially offer a long-term solution to this medical affliction. Medical therapies such as nanoparticles and botulinum neurotoxin, new technology including vibratory devices and low-intensity extracorporeal shockwave treatment, and regenerative medicine approaches that are undergoing human clinical trials.
Although preclinical data surrounding novel ED therapies are intriguing, these studies are not yet robust enough to support these endeavors outside of clinical trials and further work is ongoing.
KeywordsErectile dysfunction Low-intensity extracorporeal shockwave treatment Phosphodiesterase-5 inhibitors Stem cell therapy Platelet-rich plasma Nanoparticles
Compliance with Ethical Standards
Conflict of Interest
The authors declare that they have no conflict of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance
- 3.Corona G, Lee DM, Forti G, O'Connor DB, Maggi M, O'Neill TW, et al. Age-related changes in general and sexual health in middle-aged and older men: results from the European male ageing study (EMAS). J Sex Med. 2010;7(4 Pt 1):1362–80. https://doi.org/10.1111/j.1743-6109.2009.01601.x.CrossRefPubMedGoogle Scholar
- 6.• Lane A, Metcalfe C, Young GJ, Peters TJ, Blazeby J, Avery KN, et al. Patient-reported outcomes in the ProtecT randomized trial of clinically localized prostate cancer treatments: study design, and baseline urinary, bowel and sexual function and quality of life. BJU Int. 2016;118(6):869–79. https://doi.org/10.1111/bju.13582. ProtecT trial patient-report outcome data. CrossRefPubMedPubMedCentralGoogle Scholar
- 13.Tar M, Cabrales P, Navati M, Adler B, Nacharaju P, Friedman AJ, et al. Topically applied NO-releasing nanoparticles can increase intracorporal pressure and elicit spontaneous erections in a rat model of radical prostatectomy. J Sex Med. 2014;11(12):2903–14. https://doi.org/10.1111/jsm.12705.CrossRefPubMedPubMedCentralGoogle Scholar
- 20.• Ghanem H, Raheem AA, AbdelRahman IFS, Johnson M, Abdel-Raheem T. Botulinum neurotoxin and its potential role in the treatment of erectile dysfunction. Sex Med Rev. 2018;6(1):135–42. https://doi.org/10.1016/j.sxmr.2017.07.008. Review of potential mechanism of action of Botox for ED treatment. CrossRefPubMedGoogle Scholar
- 22.Campbell JD,De Young L, Radomski S, Alzubaidi R, Brock GB. Intracavernosal injection of botulinum toxin to improve erectile function in older rats. Presented at the Canadian Urological Association Meeting June 2016. Vancouver, BC.Google Scholar
- 23.Punjani N, Campbell JD, De, Young L, Radomski S, Alzubaidi R, Gros R, Brock GB. An evolving hypohesis on the mechanism and efficacy of intracavernosal injection of Botulinum toxin to improve erectile function: an animal study in aging rats. Presented at the World Congress of Sexual Health February 2018. Lisbon, Portugal.Google Scholar
- 25.Vardi Y, Appel B, Jacob G, Massarwi O, Gruenwald I. Can low-intensity extracorporeal shockwave therapy improve erectile function? A 6-month follow-up pilot study in patients with organic erectile dysfunction. Eur Urol. 2010;58(2):243–8. https://doi.org/10.1016/j.eururo.2010.04.004.CrossRefPubMedGoogle Scholar
- 26.Gruenwald I, Appel B, Vardi Y. Low-intensity extracorporeal shock wave therapy—a novel effective treatment for erectile dysfunction in severe ED patients who respond poorly to PDE5 inhibitor therapy. J Sex Med. 2012;9(1):259–64. https://doi.org/10.1111/j.1743-6109.2011.02498.x.CrossRefPubMedGoogle Scholar
- 27.Man L, Li G. Low-intensity extracorporeal shock wave therapy for erectile dysfunction: a systematic review and meta-analysis. Urology. 2017; https://doi.org/10.1016/j.urology.2017.09.011.
- 30.Zou ZJ, Tang LY, Liu ZH, Liang JY, Zhang RC, Wang YJ, et al. Short-term efficacy and safety of low-intensity extracorporeal shock wave therapy in erectile dysfunction: a systematic review and meta-analysis. Int Braz J Urol. 2017;43(5):805–21. https://doi.org/10.1590/S1677-5538.IBJU.2016.0245.CrossRefPubMedPubMedCentralGoogle Scholar
- 31.• Kitrey ND, Vardi Y, Appel B, Shechter A, Massarwi O, Abu-Ghanem Y, et al. Low intensity shock wave treatment for erectile dysfunction: how long does the effect last? J Urol. 2018; https://doi.org/10.1016/j.juro.2018.02.070. Long-term outcome data for Li-ESWT.
- 33.Clavell Hernandez J, Wu Q, Zhou X, Nguyen JN, Davis JW, Wang R. Penile vibratory stimulation in penile rehabilitation after radical prostatectomy: a randomized controlled trial. Presented at the World Congress of Sexual Medicine 2018, Lisbon, Portugal MP-319.Google Scholar
- 38.• Matz EL, Terlecki R, Zhang Y, Jackson J, Atala A. Stem cell therapy for erectile dysfunction. Sex Med Rev. 2018; https://doi.org/10.1016/j.sxmr.2017.12.008. Extensive review of SCT in ED.
- 39.Kendirci M, Trost L, Bakondi B, Whitney MJ, Hellstrom WJ, Spees JL. Transplantation of nonhematopoietic adult bone marrow stem/progenitor cells isolated by p75 nerve growth factor receptor into the penis rescues erectile function in a rat model of cavernous nerve injury. J Urol. 2010;184(4):1560–6. https://doi.org/10.1016/j.juro.2010.05.088.CrossRefPubMedPubMedCentralGoogle Scholar
- 40.Bivalacqua TJ, Deng W, Kendirci M, Usta MF, Robinson C, Taylor BK, et al. Mesenchymal stem cells alone or ex vivo gene modified with endothelial nitric oxide synthase reverse age-associated erectile dysfunction. Am J Physiol Heart Circ Physiol. 2007;292(3):H1278–90. https://doi.org/10.1152/ajpheart.00685.2006.CrossRefPubMedGoogle Scholar
- 44.Haahr MK, Jensen CH, Toyserkani NM, Andersen DC, Damkier P, Sørensen JA, et al. Safety and potential effect of a single intracavernous injection of autologous adipose-derived regenerative cells in patients with erectile dysfunction following radical prostatectomy: an open-label phase I clinical trial. EBioMedicine. 2016;5:204–10. https://doi.org/10.1016/j.ebiom.2016.01.024.CrossRefPubMedPubMedCentralGoogle Scholar
- 45.• Yiou R, Hamidou L, Birebent B, Bitari D, Lecorvoisier P, Contremoulins I, et al. Safety of intracavernous bone marrow-mononuclear cells for postradical prostatectomy erectile dysfunction: an open dose-escalation pilot study. Eur Urol. 2016;69(6):988–91. https://doi.org/10.1016/j.eururo.2015.09.026. Most rigorously performed human trial of SCT for ED. CrossRefPubMedGoogle Scholar
- 46.Campbell JD, Burnett AL. Neuroprotective and nerve regenerative approaches for treatment of erectile dysfunction after cavernous nerve injury. Int J Mol Sci. 2017;18(8) https://doi.org/10.3390/ijms18081794.
- 49.Patel VR, Samavedi S, Bates AS, Kumar A, Coelho R, Rocco B, et al. Dehydrated human amnion/chorion membrane allograft nerve wrap around the prostatic neurovascular bundle accelerates early return to continence and potency following robot-assisted radical prostatectomy: propensity score-matched analysis. Eur Urol. 2015;67(6):977–80. https://doi.org/10.1016/j.eururo.2015.01.012.CrossRefPubMedGoogle Scholar
- 50.• Ogaya-Pinies G, Palayapalam-Ganapathi H, Rogers T, Hernandez-Cardona E, Rocco B, Coelho RF, et al. Can dehydrated human amnion/chorion membrane accelerate the return to potency after a nerve-sparing robotic-assisted radical prostatectomy? Propensity score-matched analysis. J Robot Surg. 2017; https://doi.org/10.1007/s11701-017-0719-8. Large human trial using dHACM during radical prostatectomy.
- 51.Epifanova MV, Chalyi ME, Krasnov AO. Investigation of mechanisms of action of growth factors of autologous platelet-rich plasma used to treat erectile dysfunction. Urologiia. 2017;(4):46–8.Google Scholar
- 54.Wu YN, Wu CC, Sheu MT, Chen KC, Ho HO, Chiang HS. Optimization of platelet-rich plasma and its effects on the recovery of erectile function after bilateral cavernous nerve injury in a rat model. J Tissue Eng Regen Med. 2016;10(10):E294–304. https://doi.org/10.1002/term.1806.CrossRefPubMedGoogle Scholar
- 57.McVary A CA, Le B. Induction of novel shape memory alloy penile prosthesis. World Congress of Sexual Medicine; Lisbon, Portugal.February 2018.Google Scholar
- 58.• SMSNA Position Statement on Restorative Therapies for ED. http://www.smsna.org/V1/news/433-smsna-position-statement-on-restorative-therapies-for-ed. 2018. Accessed may 2, 2018. Current SMSNA position for restorative therapies for ED.